Connect with us

Stocks to Watch

UBER stock in Focus Ahead of Q3 Earnings

Joe Samuel



Uber stock price

Struggle To Profitability Continues

Uber Technologies Inc. (NYSE:UBER) stock has been on a downward spiral having lost 35% since its IPO. The company has continues to grapple to demonstrate a path to profitability and investors are pessimistic about the company. As a result, investors will be looking at the Q3 2019 earnings when the company reports its results on November 4. 

Analysts expect Uber to post losses in Q3

When the company releases the results on Monday analysts expect the company to post an adjusted loss of $0.83 per share on revenue of $3.75 billion. This is however not surprising considering losses are common for tech companies in the growth phase. However, the major concern among investors is the lack of a clear strategy to turn the company into profitability. 

The uncertainty about its path to profitability has led to the stock to continue bleeding. With the earnings report, the company should drive out the notion that its business is softening. When the company reported its Q2 earnings there was no assurance on the same with adjusted YoY revenue dropping 12%.

[REPORT] Apple, Disney, Netflix, Amazon, NBC, Hulu & More are All Competing Within the Global Video Streaming Market and They All Need the Same Thing…

Uber CEO optimistic of about growth of the platform

Although the company is facing profitability challenges its CEO Dara Khosrowshahi holds a different view. Khosrowshahi is urging investors to concentrate on the capability of Uber’s evolving platform. He says that the platform will soon be part of the biggest transport ecosystem. This includes the fast-growing Uber Eats segment, Freight delivery, ride-sharing services electric scooter and driverless cars.

Uber’s latest addition to the expansion of its services is Cornershop. This is a service helping food retailers, pharmacies and supermarket chains to deliver their products. This is perhaps possible considering the tech company has revolutionized how people move around in major cities.

The company controls around 65% of the ride-sharing market in Europe, Latin America, Australia, and North America. However, there is growing competition from other emerging ride-sharing companies. Uber’s largest competitor is Lyft Inc. (NASDAQ: LYFT) which is almost turning a profit. On Wednesday Lyft released Q3 results that topped analyst forecasts.

[REPORT] Apple, Disney, Netflix, Amazon, NBC, Hulu & More are All Competing Within the Global Video Streaming Market and They All Need the Same Thing…

Continue Reading
Click to comment


Stock Price Friday Update – November 8, 2019

Joe Samuel



penny stocks news

Will Apple Inc.’s (AAPL) Stock Price Head Higher As Cord Cutting Continues?

Thanks to more attention from entertainment moguls, we’re seeing the advent of new services. These come from the likes of NBC, Disney, HBO and yes, Apple. Even with this being the case, the “cord-cutting” trend doesn’t appear to be slowing down anytime soon. What other companies are influenced by this trend?

See For Yourself

3 Biotech Stocks to Watch Before Thanksgiving

Biotech is a sector that certainly turns a lot of head and has managed to create a lot of value for investors over the years. On that note, here is a look at three biotech stocks that should be watched closely by investors.

Continue Reading

3 Defense Stocks to Watch in November

Over the years it has become abundantly clear that defense spending is going to rise every year and hence, defense stocks have naturally emerged as some of the safest investments in the market. However, the current unstable geopolitical situation in different corners of the world could lead to even more defense spending, if a Bank of America analyst is to be believed.

Click To Read More

Continue Reading


3 Popular Biotech Stocks To Watch in November

Joe Samuel



Over the years, the biotech sector has been a bit of a gold mine when it comes to stocks and thousands of investors have been able to make significant profits by backing the right companies. The innovative solutions and technical advancements that have been brought into the sector by different companies is another factor behind the continued growth.

However, it needs to be mentioned that when it comes to investing in the right stock, an investor needs to conduct his research and watch the market closely. On that note, here is a look at three biotech stocks that could be tracked after their latest updates.

Pharmacyte Biotech (PMCB)

PharmaCyte announced today that its partner, Austrianova Singapore (Austrianova), has successfully completed the encapsulation of the cells from PharmaCyte’s Master Cell Bank in the second of two staggered and back-to-back manufacturing runs for the production of PharmaCyte’s clinical trial product. This product will be used for PharmaCyte’s planned clinical trial in patients with locally advanced, inoperable pancreatic cancer (LAPC).

Why is this so pivotal for the company? Aside from getting one step closer to a confirmed IND submission, this shows that the company’s able to replicate its cell encapsulation process. It may not appear as a big deal on the surface but for those who know biotechnology, the whole process of bringing a successful treatment to market can hinge on the ability to duplicate it hundreds, if not thousands of times.

Here’s where it may get even more exciting. Company CEO Ken Waggoner said, “We are anxiously awaiting the completion of the second of the two back-to-back manufacturing runs and the results from the FDA required testing on each of those runs. Once the information from that testing is available, it will be incorporated into our Investigational New Drug application (IND) for submission to the FDA.”

FOR SUBMISSION TO THE FDA,” once testing information is available. Obviously, with early-stage biotech, the proof is in the pudding. Right now Pharmacyte (PMCB) could be looking at its next milestone.

Tonix Pharmaceuticals (TNXP)

The first biotech stock to consider is that of Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP), which made a major announcement with regards to its stock on Thursday. The clinical-stage biopharmaceutical biotech firm announced that its outstanding common stock is going to undergo a 1 to 10 reverse split. Traders need to note that the split will go into effect from November 1.

top biotech stocks to buy now

This particular move has been initiated by Tonix to possible ensure that the bid price of its stock does not go below the stipulated $1. The board of directors at Tonix had approved the reverse split of the stock and it remains to be seen how the stock moves over the coming days. This is a stock that should definitely be watched over the coming days.

 CHF Solutions (CHFS)

The other biotech stock that is in the news today is that of CHF Solutions Inc (NASDAQ:CHFS). This morning the company announced that is going to change some aspects of its sales force in order to enhance its effectiveness.

The news resulted in a major rally in the stock and it has gained as much as 40% on Friday, after gaining as much as  106% earlier in session. The company stated in its press release that the focus of the sales force is going to be moved more towards its pediatrics and cardiac surgery products. The clearance of a 510(K) by the FDA is expected to come through soon and once that happens, the changeover will go into effect.

breakthrough biotech stocks to watch

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.

Continue Reading


Roku (ROKU) Stock Price Soars in October: What’s Next?

Joe Samuel



ROKU stock price movement

Video streaming device maker and platform Roku Inc (NASDAQ:ROKU) had been one of the best-performing stocks this year due to its impressive growth in recent quarters. In a new development, the Roku stock experienced another impressive rally on Monday and jumped by as much as 10% as investors piled on to the stock following bullish comments from an analyst.

What Are Analysts Saying?

Ziv Israel, who is an analyst at Bank of America, sent out a highly bullish note with regards to Roku and that seems to have triggered the rally. In the same note, Israel stated that the bank is going to initiate coverage on the stock and also rated the stock as a ‘buy’.

A few weeks back the Roku stock had suffered a bit of a slump due to the emergence of competition in the streaming devices market. The new product from Comcast, which is also going to be given away for free to internet-only customers, had created some pessimism in the market.

The $40 Billion Dollar Content Gold Rush

However, Israel believes that the potential of the competition is being overstated at this point. He said that Roku has a competitive advantage by virtue of its operating system for streaming and in addition to that Comcast’s free offering could end up costing customers more.

Citing these factors, the analyst went on to classify the Roku stock as a ‘buy’ and set the 12-month target price at $154. That being said, it is important to keep in mind that the streaming industry and the whole market by extension, are changing at a rapid pace. Tech giants like Apple are entering the free and it is not completely inconceivable that they are going to come up with their own devices.

The company has projected Q3 2019 revenues to be in the range between $250 million and $255 million. If the company manages to generate $252.5 million (midway), then it would reflect year on year growth of 46%.

The stock has soared over 45% since the beginning of October. Moreover, the stock is just 17% away from its all-time high of $176.55.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!

Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (


Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact